Biocryst Pharmaceuticals (BCRX) Operating Expenses (2010 - 2026)

Biocryst Pharmaceuticals has reported Operating Expenses for 17 years, with the latest figure at $858.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 590.24% year-over-year to $858.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 169.51% YoY), and the FY2025 full-year result was $533.8 million, up 17.78% from the prior year.
• Operating Expenses for Q1 2026 stood at $858.0 million, up from $146.2 million in the prior quarter.
• The five-year high for Operating Expenses was $858.0 million in Q1 2026, with the low at $93.3 million in Q3 2022.
• Historically, Operating Expenses has averaged $158.8 million across 5 years, with a median of $109.4 million in 2024.
• Annual changes were most pronounced in 2023 — Operating Expenses fell 2.69% — and 2026, when it surged 590.24%.
• Biocryst Pharmaceuticals' Operating Expenses stood at $125.9 million in 2022, then rose by 8.12% to $136.1 million in 2023, then fell by 0.02% to $136.0 million in 2024, then advanced by 7.44% to $146.2 million in 2025, then surged by 487.0% to $858.0 million in 2026.
• The last three Operating Expenses figures came in at $858.0 million (Q1 2026), $146.2 million (Q4 2025), and $129.8 million (Q3 2025), per Business Quant data.